Abstract
Five isoforms of protein mannosyltransferase (Pmt) O-mannosylate secretory proteins in Candida albicans. pmt mutants were differentially defective for biofilm formation on plastic in static and flow-through systems, and a Pmt inhibitor blocked early stages of biofilm formation. Conceptually, Pmt inhibition may prevent surface anchoring and biofilm-dependent resistance of fungal pathogens.
The human fungal pathogen Candida albicans is able to form biofilms on a variety of inert surfaces, including materials used for medical implants, e.g., central venous catheters (7, 8, 17), which consist of a bottom layer of mostly yeast cells, an upper layer containing mostly hyphal cells, and yet-undefined extracellular material (2, 4, 5). C. albicans biofilms are highly resistant to most antifungals, but the mechanisms of resistance are not clear (1, 3, 5, 6, 12, 13).
Some compounds blocking hyphal development and consequently biofilm formation and biofilm-mediated resistance have been described (11, 16). We speculated that surface mannoproteins could also represent targets for biofilm inhibitors. Surface mannoproteins in fungi are typically O mannosylated at serine or threonine residues, and protein O-mannosyltransferases (Pmt proteins) initiate this modification in the endoplasmic reticulum (9). We previously characterized the PMT gene family of C. albicans, which encodes five Pmt isoforms (15, 19, 20). One isoform, Pmt2p, was required for growth, while the Pmt1p and Pmt4p isoforms contributed to high levels of basal resistance towards a range of antifungals. Most pmt mutants (except pmt5) were defective in hyphal formation in some conditions, and all five Pmt isoforms contributed to virulence (15, 18).
We compared the biofilm-forming ability of the control strain CAF2-1, isogenic homozygous pmt mutants (pmt1, pmt4, and pmt6), and the heterozygous PMT2/pmt2 strain (15) in a batch system. Strains were pregrown for 24 h at 37°C in SD medium (0.67% yeast nitrogen base, 2% glucose) (yeast form only) and resuspended in 5 ml phosphate-buffered saline. Cells were separated in a bath sonifier and resuspended in RPMI 1640 medium containing 2% glucose (0.165 M morpholinepropanesulfonic acid, pH 7) at 106 cells per ml. Each strain was used for inoculation of a separate 24-well-culture polystyrene dish (Falcon), adding 500 μl of the cell suspension to each well. Plates were incubated for 48 h at 37°C in a wet chamber. The medium was discarded, each well was washed with 500 μl of phosphate-buffered saline, and plates were dried for 24 h at 37°C to determine dry weights. Results were evaluated by an unpaired t test, calculating two-tail P values (GraphPad Prism 4). Clear quantitative differences were observed between biofilms of pmt mutants and the control strain (Fig. 1A). Biofilm formation of the pmt1 mutant and the heterozygous PMT2/pmt2 strain was significantly reduced, while pmt4 and pmt6 mutations caused moderate defects; in contrast, biofilm formation of the pmt5 mutant was not affected. A pmt1 pmt6 double mutant (20) revealed no additional contribution of the pmt6 mutation to the pmt1 biofilm phenotype, while the pmt4 pmt6 double mutant (14), unexpectedly, had the wild-type phenotype. To confirm mutant phenotypes, we compared biofilm formation of pmt mutants containing chromosomally integrated vectors carrying the corresponding PMT gene to that of strains carrying an empty vector (pRC18) (18). This experiment confirmed strong and moderate requirements for PMT1 and PMT4, respectively, in biofilm formation (Fig. 1B). Importantly, biofilm defects were not due to defects in growth or morphogenesis, because growth rates and hyphal formation abilities of pmt mutants were equivalent to those of the control strain during planktonic growth under the conditions used for biofilm formation (data not shown). Furthermore, electron microscopy (Philips ESEM XL30 FEG microscope) showed similar appearances of biofilms of the control, pmt4, pmt5, pmt6, and PMT2/pmt2 strains, consisting of a dense mat of intertwined hyphal filaments mixed with yeast cells. In contrast, the pmt1 mutant formed very few microcolonies on the polystyrene surface, which nevertheless consisted of both yeast and hyphal cells (Fig. 2).
FIG. 1.
Biofilm formation in polystyrene cell culture wells. (A) Wells were inoculated with 5 × 105 C. albicans cells, and biofilm formation was allowed to proceed in RPMI medium for 48 h at 37°C. Strains included the control strain CAF2-1 (+/+) and two independently constructed homozygous mutant strains: pmt1 mutants SPCa2 and SPCa3 (1/1), pmt2 heterozygotes SPCa4 and SPCa5 (2/+), pmt4 mutants SPCa6 and SPCa7 (4/4), pmt5 mutants SPCa10 and SPCa11 (5/5), pmt6 mutant SPCa8 and SPCa9 (6/6), pmt4 pmt6 mutant PP46-428 (4/4 6/6), and pmt1 pmt6 mutant CPP117 (1/1 6/6) (15). Biofilms were quantitated by dry weights of wells. Mean values and standard deviations were determined from eight independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001 (pmt mutant versus control strain). The mass of the control strain is indicated as a dashed line (wt). (B) Biofilm formation of PMT-reconstituted strains. pmt mutants containing an empty plasmid (pRC18) or a PMT-carrying plasmid, integrated in the LEU2 locus, were allowed to form biofilms in polystyrene cell culture wells. Strains included CAP1-3121(pRC18) (pmt1 [empty]), CAP1-3121(pCT30) (pmt1 [PMT1]), CAP4-2164(pRC18) (pmt4 [empty]), CAP4-2164(pSP1) (pmt4 [PMT4]), CAP2-2391(pRC18) (pmt6 [empty]), and CAP2-2391(pCT34) (pmt6 [PMT6]) (18). Dry weights of biofilms were determined, and mean values and standard deviations were calculated from at least five independent experiments. *, P < 0.05 (mutant with empty vector versus mutant carrying PMT gene).
FIG. 2.
Scanning electron microscopy of C. albicans biofilms on polystyrene. Dense biofilms of the control strain CAF2-1 (+/+) are compared to rare attached cells and microcolonies of the pmt1 mutant SPCa2.
Certain rhodanine compounds inhibit the enzymatic activity of Pmt1p, leading to pmt1 mutant phenotypes, including aminoglycoside supersensitivity, defective hypha formation under some conditions, and increased aggregation, while not affecting growth rates (13; data not shown). Addition of compound OGT2599 inhibited biofilm formation in polystyrene wells at low concentrations in a dose-dependent manner (Fig. 3). To clarify if this inhibition was caused by interference with adherence of cells or by inhibition of later stages of biofilm formation, we either added the inhibitor simultaneously with cells or after 24 h, when biofilm formation was incomplete. The results indicate that simultaneous addition of the inhibitor completely blocked biofilm formation, while after 24 h the inhibitor was ineffective (Fig. 3). Because mannoproteins synthesized during pregrowth appeared insufficient for biofilm formation, we conclude that the inhibitor blocks mannosylation of newly synthesized, biofilm-relevant proteins.
FIG. 3.
Inhibition of biofilm formation by O glycosylation inhibitor OGT2599. (A) Increasing concentrations of OGT2599 were added during addition of C. albicans CAF2-1 to polystyrene cell culture wells. Biofilm formation was allowed to proceed and was quantitated as for Fig. 1. *, P < 0.05; ***, P < 0.0001 (culture without inhibitor versus culture with added inhibitor). (B) The inhibitor OGT2599 was added at the indicated concentrations 24 h after addition of C. albicans cells. Values represent the mean ± standard deviation for at least five independent measurements. n.d., not done.
The pmt mutant strains were evaluated for their ability to form a biofilm in a continuous-flow microfermenter model. Biofilms were produced as described previously (10) except that SD medium contained 0.4% glucose, arginine (0.1 g/liter), histidine (0.1 g/liter), methionine (0.2 g/liter), and uridine (0.01 g/liter). Stationary-phase yeast cells were placed for 30 min on a slide of Thermanox plastic (a polyolefin polyester) and gently washed by dipping into SD medium (five times), and adherent cells were allowed to form a biofilm under a continuous flow of minimal medium and air. We first evaluated adherence abilities of pmt mutants in this model. The pmt1 mutant was severely impaired for adherence to Thermanox, while the pmt4, pmt5, and pmt6 mutants adhered as did the control strain (Fig. 4 A). Assessment of the heterozyous PMT2/pmt2 mutant was prevented by its occasional flocculation during planktonic growth (data not shown). The results indicate that the pmt5 and pmt6 homozygous mutants formed biofilms as efficiently as the control strain, while a twofold reduction in biofilm biomass was observed for the pmt4 mutant (Fig. 4B). Thus, in the continuous system, Pmt1p is required for early phases of biofilm formation, while Pmt4p is necessary for subsequent phases.
FIG. 4.
Defective adherence and biofilm formation of pmt mutants in the continuous-flow microfermenter model. A. Stationary-phase cells of the wild-type (CAI4) and mutant (pmt1Δ, SPCa2; pmt4Δ, SPCa6; pmt5Δ, SPCa10; pmt6Δ, SPCa8) strains were put into contact with a Thermanox slide for 30 min. Following removal of nonadherent cells, at least 10 microscope fields were counted for adherent cells. Data obtained from two independent experiments are shown as the ratio between adherent mutant and wild-type cells along with the standard deviation. B. Biofilm formation was monitored in duplicate following adhesion of yeast cells to Thermanox and growth for 41 h in the microfermenter model. Dry biomasses of the biofilms were quantified and expressed as a ratio of mutant versus wild type. This experiment is representative of the data obtained in three separate experiments.
Defective biofilm formation by pmt mutants and after Pmt inhibition may be the consequence of altered cell wall composition and overall hydrophobicity in cells defective in O mannosylation (15). Novel strategies to combat C. albicans as a commensal or infectious agent could include Pmt inhibition to prevent anchoring and biofilm formation on biological surfaces (extracellular materials and cell surfaces) and on nonbiological surfaces including medical implants. Conceivably, surface-bound or -incorporated inhibitors could protect medical devices from colonization by C. albicans. Blockage of biofilm formation by Pmt inhibition would also abolish an important mechanism of antifungal resistance (4, 5, 9, 12, 13).
Acknowledgments
We thank C. Stubberfield, UCB, for kindly supplying the Pmt1 inhibitor OGT2599.
This project was funded by EU grant MRTN-CT-2003-504148 (Galar Fungail 2) to J.F.E. and C.D. and EU grant QLK2-CT-2001-02377 (Combating MDR in Pathogens) and priority program SPP1160 by the Deutsche Forschungsgemeinschaft to J.F.E.
REFERENCES
- 1.Al-Fattani, M. A., and L. J. Douglas. 2004. Penetration of Candida biofilms by antifungal agents. Antimicrob. Agents Chemother. 48:3291-3297. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Baillie, G. S., and L. J. Douglas. 1999. Role of dimorphism in the development of Candida albicans biofilms. J. Med. Microbiol. 48:671-679. [DOI] [PubMed] [Google Scholar]
- 3.Baillie, G. S., and L. J. Douglas. 1999. Candida biofilms and their susceptibilities to antifungal agents. Methods Enzymol. 310:644-656. [DOI] [PubMed] [Google Scholar]
- 4.Baillie, G. S., and L. J. Douglas. 2000. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J. Antimicrob. Ther. 46:397-403. [DOI] [PubMed] [Google Scholar]
- 5.Chandra, J., D. M. Kuhn, P. K. Mukherjee, L. L. Hoyer, T. McCormick, and M. A. Ghannoum. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183:5385-5394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.d′Enfert, C. 2006. Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr. Drug Targets 7:465-470. [DOI] [PubMed] [Google Scholar]
- 7.Donlan, R. M., and J. W. Costerdon. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167-193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Douglas, L. J. 2003. Candida biofilms and their role in infection. Trends Microbiol. 11:30-36. [DOI] [PubMed] [Google Scholar]
- 9.Ernst, J. F., and S. K.-H. Prill. 2001. O-glycosylation. Med. Mycol. 39(Suppl. I):67-74. [PubMed] [Google Scholar]
- 10.García-Sanchez, S., S. Aubert, I. Iraqui, G. Janbon, J.-M. Ghigo, and C. D′Enfert. 2004. Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns. Eukar. Cell 3:536-545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Hogan, D. A., A. Vik, and R. Kolter. 2004. A Pseudomonas aeruginosa quorum sensing molecule influences Candida albicans morphology. Mol. Microbiol. 54:1212-1223. [DOI] [PubMed] [Google Scholar]
- 12.Jabra-Rizk, M. A., W. A. Falkler, and T. F. Meiller. 2004. Fungal biofilms and drug resistance. Emerg. Infect. Dis. 10:14-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Mukherjee, P. K., J. Chandra, D. M. Kuhn, and M. A. Ghannoum. 2003. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71:4333-4340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Orchard, M. G., J. C. Neuss, C. M. Galley, A. Carr, D. W. Porter, P. Smith, D. I. Scopes, D. Haydon, K. Vousden, C. R. Stubberfield, K. Young, and M. Page. 2004. Rhodanine-3-acetic acid derivatives as inhibitors of fungal protein mannosyl transferase 1 (PMT1). Bioorg. Med. Chem. Lett. 14:3975-3978. [DOI] [PubMed] [Google Scholar]
- 15.Prill, S. K.-H., B. Klinkert, C. Timpel, C. A. Gale, K. Schröppel, and J. F. Ernst. 2005. PMT family of Candida albicans: five protein mannosyltransferase isoforms affect growth, morphogenesis and antifungal resistance. Mol. Microbiol. 55:546-560. [DOI] [PubMed] [Google Scholar]
- 16.Ramage, G., S. P. Saville, B. L. Wickes, and J. L. López-Ribot. 2002. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl. Environ. Microbiol. 68:5459-5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Ramage, G., S. P. Saville, D. P. Thomas, and J. L. López-Ribot. 2005. Candida biofilms: an update. Eukaryot. Cell 4:633-638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Rouabhia, M., M. Schaller, C. Corbucci, A. Vecchiarelli, S. K.-H. Prill, L. Giasson, and J. F. Ernst. 2005. Virulence of the fungal pathogen Candida albicans requires the five isoforms of protein mannosyltransferases. Infect. Immun. 73:4571-4580. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Timpel, C., S. Strahl-Bolsinger, K. Ziegelbauer, and J. F. Ernst. 1998. Multiple functions of Pmt1p-mediated protein O-mannosylation in the fungal pathogen Candida albicans. J. Biol. Chem. 273:20837-20846. [DOI] [PubMed] [Google Scholar]
- 20.Timpel, C., S. Zink, S. Strahl-Bolsinger, K. Schröppel, and J. F. Ernst. 2000. Morphogenesis, adhesive properties, and antifungal resistance depend on the Pmt6 protein mannosyltransferase in the fungal pathogen Candida albicans. J. Bacteriol. 182:3063-3071. [DOI] [PMC free article] [PubMed] [Google Scholar]




